PR Newswire BiotechOriginal article
BioAge Labs administra la primera dosis a un participante en el ensayo de fase 2 de BGE-102
Phase 2BGE-102Positive
AI Analysis
Summary
BioAge Labs, in partnership with HitGen, initiated dosing in a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor being developed for cardiovascular risk reduction.
Clinical Trial Data
Phase
2
Outcome Details
First dose administered to participant
Importance:5/10
Sentiment:
0.30
Phase 2NLRP3 inhibitorcardiovascularoral drugtrial initiation
Related Companies
Read the original article
Published by PR Newswire Biotech on July 14, 2026 1:16 PM